MD3558391T2 - Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora - Google Patents
Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestoraInfo
- Publication number
- MD3558391T2 MD3558391T2 MDE20191243T MDE20191243T MD3558391T2 MD 3558391 T2 MD3558391 T2 MD 3558391T2 MD E20191243 T MDE20191243 T MD E20191243T MD E20191243 T MDE20191243 T MD E20191243T MD 3558391 T2 MD3558391 T2 MD 3558391T2
- Authority
- MD
- Moldova
- Prior art keywords
- immunoconjugates
- adam9
- relates
- chain variable
- methods
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title abstract 7
- 101000832769 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 title abstract 4
- 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 101800001224 Disintegrin Proteins 0.000 abstract 1
- 241000282567 Macaca fascicularis Species 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000054116 human ADAM9 Human genes 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
Prezenta invenţie se referă la imunoconjugaţi care cuprind un anticorp sau un fragment al acestuia capabil să se lege în mod specific la "Proteina 9 care conţine domeniul de dezintegrină şi metaloproteinază" ("ADAM9") conjugat cu cel puţin un agent farmacologic. Invenţia se referă în special la astfel de imunoconjugaţi care sunt reactivi încrucişat cu ADAM9 umană şi ADAM9 de primată non-umană (cum ar fi o maimuţă cynomolgus). Invenţia se referă în plus la toţi astfel de imunoconjugaţi care cuprind un domeniu variabil al lanţului uşor (VL) şi/sau un domeniu variabil al lanţului greu (VH) care a fost umanizat şi în mod opţional deimunizat astfel încât să prezinte o imunogenitate redusă la administrarea unor astfel de imunoconjugaţi la un subiect destinatar. Invenţia se referă, de asemenea, la compoziţii farmaceutice ce conţin oricare dintre astfel de imunoconjugaţi şi la metodele care implică utilizarea oricărora dintre aceşti imunoconjugaţi în tratamentul cancerului sau a altori boli şi condiţii.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662438488P | 2016-12-23 | 2016-12-23 | |
US201762480201P | 2017-03-31 | 2017-03-31 | |
PCT/US2017/067823 WO2018119196A1 (en) | 2016-12-23 | 2017-12-21 | Immunoconjugates targeting adam9 and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3558391T2 true MD3558391T2 (ro) | 2022-05-31 |
Family
ID=61025051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20191243T MD3558391T2 (ro) | 2016-12-23 | 2017-12-21 | Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210388102A1 (ro) |
EP (1) | EP3558391B1 (ro) |
JP (1) | JP7170642B2 (ro) |
CN (1) | CN110267685B (ro) |
DK (1) | DK3558391T3 (ro) |
ES (1) | ES2912266T3 (ro) |
HR (1) | HRP20220550T1 (ro) |
HU (1) | HUE058664T2 (ro) |
LT (1) | LT3558391T (ro) |
MD (1) | MD3558391T2 (ro) |
PL (1) | PL3558391T3 (ro) |
PT (1) | PT3558391T (ro) |
RS (1) | RS63154B1 (ro) |
SI (1) | SI3558391T1 (ro) |
TW (1) | TWI783957B (ro) |
WO (1) | WO2018119196A1 (ro) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019140141A1 (en) | 2018-01-12 | 2019-07-18 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
MX2020013466A (es) * | 2018-06-26 | 2021-04-19 | Immunogen Inc | Inmunoconjugados dirigidos a adam9 y métodos para usarlos. |
AU2020240310A1 (en) * | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
KR20220010481A (ko) | 2019-03-29 | 2022-01-25 | 이뮤노젠 아이엔씨 | 비정상 세포 성장의 억제 또는 증식성 질환의 치료를 위한 세포독성 비스-벤조디아제핀 유도체 및 세포결합제와 이의 접합체 |
JP2022529854A (ja) | 2019-04-26 | 2022-06-24 | イミュノジェン・インコーポレーテッド | カンプトテシン誘導体 |
CN110713983B (zh) * | 2019-11-04 | 2022-06-10 | 深圳市体内生物医药科技有限公司 | 一种表达透明质酸酶的免疫细胞及其应用 |
JP2024512392A (ja) | 2021-03-08 | 2024-03-19 | イミュノジェン・インコーポレーテッド | がんの治療のためのadam9を標的とする免疫抱合体の有効性を増加させるための方法 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
US20030091568A1 (en) | 2000-04-07 | 2003-05-15 | Jurgen Frey | Inhibitors for the formation of soluble human CD23 |
EP1142910A1 (en) | 2000-04-07 | 2001-10-10 | Jürgen Prof. Dr. Frey | Inhibitors for the formation of soluble human CD23 |
JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン,エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
CA2470763A1 (en) | 2001-12-18 | 2003-06-26 | Mondobiotech Laboratories Anstalt | Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US20040092466A1 (en) | 2002-11-11 | 2004-05-13 | Isis Pharmaceuticals Inc. | Modulation of ADAM9 expression |
AU2003259163B2 (en) | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
DE10337368A1 (de) * | 2003-08-08 | 2005-03-03 | Technische Universität Dresden | Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
WO2005091823A2 (en) | 2004-03-01 | 2005-10-06 | The Regents Of The University Of California | The use of lunasin peptide as a transcriptional activator to prevent cancer and related methods for treatment, monitoring and prognosis |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2596273C (en) * | 2005-02-02 | 2017-11-14 | Raven Biotechnologies, Inc. | Adam-9 modulators |
US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
ES2567402T3 (es) | 2006-05-30 | 2016-04-22 | Genentech, Inc. | Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos |
WO2007143752A2 (en) | 2006-06-09 | 2007-12-13 | The Regents Of The University Of California | Targets in breast cancer for prognosis or therapy |
KR101443214B1 (ko) | 2007-01-09 | 2014-09-24 | 삼성전자주식회사 | 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이 |
PT2019104E (pt) | 2007-07-19 | 2013-12-03 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica |
GB2453589A (en) | 2007-10-12 | 2009-04-15 | King S College London | Protease inhibition |
US8101361B2 (en) | 2008-03-10 | 2012-01-24 | National Jewish Health | Markers for diagnosis of pulmonary inflammation and methods related thereto |
WO2009126616A2 (en) | 2008-04-07 | 2009-10-15 | Zymogenetics, Inc. | Thrombin activator compostions and methods of making and using the same |
US20090285840A1 (en) | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
CN104258413A (zh) | 2008-04-30 | 2015-01-07 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
CN104524592B (zh) | 2008-04-30 | 2018-06-05 | 伊缪诺金公司 | 交联剂和它们的用途 |
US20110081347A1 (en) | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
US20110129450A1 (en) | 2008-08-01 | 2011-06-02 | Orly Lazarov | Method of promoting neurogenesis by modulating secretase activities |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
US20100112713A1 (en) | 2008-11-05 | 2010-05-06 | The Texas A&M University System | Methods For Detecting Colorectal Diseases And Disorders |
WO2010065882A1 (en) | 2008-12-04 | 2010-06-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
SG2014009138A (en) | 2009-02-05 | 2014-03-28 | Immunogen Inc | Novel benzodiazepine derivatives |
KR101947176B1 (ko) | 2009-06-03 | 2019-02-12 | 이뮤노젠 아이엔씨 | 접합 방법 |
CA2789679A1 (en) | 2010-02-11 | 2011-08-18 | University Of Southern California | Modified adam disintegrin domain polypeptides and uses thereof |
ES2895480T3 (es) | 2010-03-04 | 2022-02-21 | Macrogenics Inc | Anticuerpos reactivos con B7-H3, fragmentos inmunológicamente activos de los mismos y usos de los mismos |
AU2011239525B2 (en) | 2010-04-15 | 2015-04-09 | Medimmune Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
SG191965A1 (en) | 2011-02-15 | 2013-08-30 | Immunogen Inc | Methods of preparation of conjugates |
UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US20130130355A1 (en) | 2011-09-28 | 2013-05-23 | Armune Biosciences, Inc. | Method and system of particle-phage epitope complex |
US20140342946A1 (en) | 2011-12-31 | 2014-11-20 | Moni Abraham Kuriakose | Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer |
US9534058B2 (en) | 2012-02-08 | 2017-01-03 | Abbvie Stemcentrx Llc | Anti-CD324 monoclonal antibodies and uses thereof |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
EP2943585B1 (en) | 2013-01-09 | 2018-07-11 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles |
CA2900764A1 (en) | 2013-02-08 | 2014-08-14 | Stemcentrx, Inc. | Novel multispecific constructs |
JPWO2014168154A1 (ja) | 2013-04-08 | 2017-02-16 | 三菱レイヨン株式会社 | 眼疾患を評価するためのマイクロアレイ及び眼疾患の評価方法 |
ES2902420T3 (es) | 2013-05-13 | 2022-03-28 | Univ Tufts | Composiciones para el tratamiento del cáncer que expresa ADAM8 |
WO2014205293A1 (en) | 2013-06-19 | 2014-12-24 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis |
US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
TW201609152A (zh) * | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
TWI757759B (zh) | 2014-09-03 | 2022-03-11 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
TW201613930A (en) | 2014-09-03 | 2016-04-16 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
SG11201703803WA (en) | 2014-11-11 | 2017-06-29 | Amunix Operating Inc | Targeted xten conjugate compositions and methods of making same |
CA2988806A1 (en) | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Conjugates of cysteine engineered antibodies |
-
2017
- 2017-12-21 US US16/469,494 patent/US20210388102A1/en active Pending
- 2017-12-21 JP JP2019533514A patent/JP7170642B2/ja active Active
- 2017-12-21 HU HUE17835533A patent/HUE058664T2/hu unknown
- 2017-12-21 EP EP17835533.5A patent/EP3558391B1/en active Active
- 2017-12-21 PL PL17835533T patent/PL3558391T3/pl unknown
- 2017-12-21 RS RS20220395A patent/RS63154B1/sr unknown
- 2017-12-21 LT LTEPPCT/US2017/067823T patent/LT3558391T/lt unknown
- 2017-12-21 HR HRP20220550TT patent/HRP20220550T1/hr unknown
- 2017-12-21 PT PT178355335T patent/PT3558391T/pt unknown
- 2017-12-21 ES ES17835533T patent/ES2912266T3/es active Active
- 2017-12-21 DK DK17835533.5T patent/DK3558391T3/da active
- 2017-12-21 SI SI201731135T patent/SI3558391T1/sl unknown
- 2017-12-21 CN CN201780079982.XA patent/CN110267685B/zh active Active
- 2017-12-21 WO PCT/US2017/067823 patent/WO2018119196A1/en unknown
- 2017-12-21 TW TW106145085A patent/TWI783957B/zh active
- 2017-12-21 MD MDE20191243T patent/MD3558391T2/ro unknown
Also Published As
Publication number | Publication date |
---|---|
ES2912266T3 (es) | 2022-05-25 |
JP2020504607A (ja) | 2020-02-13 |
HUE058664T2 (hu) | 2022-09-28 |
WO2018119196A1 (en) | 2018-06-28 |
RS63154B1 (sr) | 2022-05-31 |
PL3558391T3 (pl) | 2022-05-16 |
JP7170642B2 (ja) | 2022-11-14 |
TWI783957B (zh) | 2022-11-21 |
EP3558391B1 (en) | 2022-02-02 |
DK3558391T3 (da) | 2022-05-09 |
CN110267685B (zh) | 2023-06-20 |
CN110267685A (zh) | 2019-09-20 |
TW201822821A (zh) | 2018-07-01 |
SI3558391T1 (sl) | 2022-06-30 |
HRP20220550T1 (hr) | 2022-06-10 |
PT3558391T (pt) | 2022-05-05 |
EP3558391A1 (en) | 2019-10-30 |
US20210388102A1 (en) | 2021-12-16 |
WO2018119196A8 (en) | 2019-06-20 |
LT3558391T (lt) | 2022-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3558391T2 (ro) | Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora | |
EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
NZ748314A (en) | Anti-cmet antibody drug conjugates and methods for their use | |
MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
EA201691059A1 (ru) | Соединения-пептидомиметики и содержащие их конъюгаты антитело-лекарственное средство | |
PE20190353A1 (es) | Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos | |
PE20170912A1 (es) | Conjugados de anticuerpo-farmaco | |
UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
EA201300016A1 (ru) | Конъюгаты антител человека против тканевого фактора с лекарственными препаратами | |
RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
BR112012019098A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo | |
WO2013106485A3 (en) | Ultralong complementarity determining regions and uses thereof | |
EA201691251A1 (ru) | Цитотоксические пептиды и их конъюгаты | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
EA201992350A1 (ru) | Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3 | |
EA201792300A1 (ru) | Комбинации иммуноконъюгата к cd37 и антитела к cd20 | |
MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
EA202191244A1 (ru) | Новые цитостатические конъюгаты с лигандами интегрина | |
MX2017012615A (es) | Anticuerpo anti-notch4 humano. | |
EA202092085A1 (ru) | ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ | |
PH12020551037A1 (en) | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods | |
MX2021015974A (es) | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados. | |
MX2020013466A (es) | Inmunoconjugados dirigidos a adam9 y métodos para usarlos. | |
MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. |